Loading…
Plasma CRABP2 as a Novel Biomarker in Patients with Non-Small Cell Lung Cancer
Lung cancer is the most common cause of cancer-related mortality worldwide. We previously reported the identification of a new genetic marker, cellular retinoic acid binding protein 2 (CRABP2), in lung cancer tissues. The aim of this study was to assess plasma levels of CRABP2 from patients with non...
Saved in:
| Published in: | Journal of Korean medical science 2018, 33(26), , pp.1-9 |
|---|---|
| Main Authors: | , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c433t-9e7b09c98d92a5dc24132931b990e1831e01b425254982a72f554ccaf7e127a93 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c433t-9e7b09c98d92a5dc24132931b990e1831e01b425254982a72f554ccaf7e127a93 |
| container_end_page | e178 |
| container_issue | 26 |
| container_start_page | e178 |
| container_title | Journal of Korean medical science |
| container_volume | 33 |
| creator | Kim, Do Jun Kim, Woo Jin Lim, Myoungnam Hong, Yoonki Lee, Seung-Joon Hong, Seok-Ho Heo, Jeongwon Lee, Hui-Young Han, Seon-Sook |
| description | Lung cancer is the most common cause of cancer-related mortality worldwide. We previously reported the identification of a new genetic marker, cellular retinoic acid binding protein 2 (CRABP2), in lung cancer tissues. The aim of this study was to assess plasma levels of CRABP2 from patients with non-small cell lung cancer (NSCLC).
Blood samples that were collected from 122 patients with NSCLC between September 2009 and September 2013 were selected for the analysis, along with samples from age- (± 5 years), sex-, and cigarette smoking history (± 10 pack-years [PY])-matched controls from the Korea Biobank Network. The control specimens were from patients who were without malignancies or pulmonary diseases. We measured plasma levels of CRABP2 using commercially available enzyme-linked immunosorbent assay kits.
The mean age of the NSCLC patients was 71.8 ± 8.9 years, and the median cigarette smoking history was 32 PY (range, 0-150 PY). Plasma CRABP2 levels were significantly higher in patients with NSCLC than in the matched controls (37.63 ± 28.71 ng/mL vs. 24.09 ± 21.09 ng/mL,
< 0.001). Higher plasma CRABP2 levels were also correlated with lower survival rates in NSCLC patients (
= 0.014).
Plasma CRABP2 levels might be a novel diagnostic and prognostic marker in NSCLC. |
| doi_str_mv | 10.3346/jkms.2018.33.e178 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_nrf_k</sourceid><recordid>TN_cdi_nrf_kci_oai_kci_go_kr_ARTI_4231877</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2058506001</sourcerecordid><originalsourceid>FETCH-LOGICAL-c433t-9e7b09c98d92a5dc24132931b990e1831e01b425254982a72f554ccaf7e127a93</originalsourceid><addsrcrecordid>eNpVUctOWzEUtFArXu0HsEFetoubnuNHbG8qhatCkSIaUbq2HMcXTO4D7Buq_j0OoajdnIc8M8ejIeQEYcK5mH65X3d5wgB1WScBld4jhyiNrqZcqndlBsRKGy4OyFHO9wBMSsb3yQEzhoPQ5pBcLVqXO0fr69nZglGXqaNXw1No6VkcOpfWIdHY04UbY-jHTH_H8a4A-upn59qW1qGU-aa_pbXrfUgfyPvGtTl8fO3H5Nf5t5v6ezX_cXFZz-aVF5yPlQlqCcYbvTLMyZVnAjkzHJfGQEDNMQAuBZNMCqOZU6yRUnjvGhWQKWf4Mfm80-1TY9c-2sHFl3472HWys-ubSysYR61UwX7dYR82yy6sfPGRXGsfUiz-_rww_3_p413RebJTQFACisCnV4E0PG5CHm0Xsy_OXR-GTbYMpJYwBcACxR3UpyHnFJq3Mwh2m5ndZma3mZXVbjMrnNN___fG-BsSfwbjL5EV</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2058506001</pqid></control><display><type>article</type><title>Plasma CRABP2 as a Novel Biomarker in Patients with Non-Small Cell Lung Cancer</title><source>PubMed Central</source><creator>Kim, Do Jun ; Kim, Woo Jin ; Lim, Myoungnam ; Hong, Yoonki ; Lee, Seung-Joon ; Hong, Seok-Ho ; Heo, Jeongwon ; Lee, Hui-Young ; Han, Seon-Sook</creator><creatorcontrib>Kim, Do Jun ; Kim, Woo Jin ; Lim, Myoungnam ; Hong, Yoonki ; Lee, Seung-Joon ; Hong, Seok-Ho ; Heo, Jeongwon ; Lee, Hui-Young ; Han, Seon-Sook</creatorcontrib><description>Lung cancer is the most common cause of cancer-related mortality worldwide. We previously reported the identification of a new genetic marker, cellular retinoic acid binding protein 2 (CRABP2), in lung cancer tissues. The aim of this study was to assess plasma levels of CRABP2 from patients with non-small cell lung cancer (NSCLC).
Blood samples that were collected from 122 patients with NSCLC between September 2009 and September 2013 were selected for the analysis, along with samples from age- (± 5 years), sex-, and cigarette smoking history (± 10 pack-years [PY])-matched controls from the Korea Biobank Network. The control specimens were from patients who were without malignancies or pulmonary diseases. We measured plasma levels of CRABP2 using commercially available enzyme-linked immunosorbent assay kits.
The mean age of the NSCLC patients was 71.8 ± 8.9 years, and the median cigarette smoking history was 32 PY (range, 0-150 PY). Plasma CRABP2 levels were significantly higher in patients with NSCLC than in the matched controls (37.63 ± 28.71 ng/mL vs. 24.09 ± 21.09 ng/mL,
< 0.001). Higher plasma CRABP2 levels were also correlated with lower survival rates in NSCLC patients (
= 0.014).
Plasma CRABP2 levels might be a novel diagnostic and prognostic marker in NSCLC.</description><identifier>ISSN: 1011-8934</identifier><identifier>EISSN: 1598-6357</identifier><identifier>DOI: 10.3346/jkms.2018.33.e178</identifier><identifier>PMID: 29930489</identifier><language>eng</language><publisher>Korea (South): The Korean Academy of Medical Sciences</publisher><subject>Aged ; Aged, 80 and over ; Biomarkers, Tumor ; Carcinoma, Non-Small-Cell Lung ; Female ; Humans ; Lung Neoplasms ; Male ; Middle Aged ; Original ; Prognosis ; Receptors, Retinoic Acid - blood ; Republic of Korea ; Survival Rate ; 의학일반</subject><ispartof>Journal of Korean Medical Science, 2018, 33(26), , pp.1-9</ispartof><rights>2018 The Korean Academy of Medical Sciences. 2018 The Korean Academy of Medical Sciences</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c433t-9e7b09c98d92a5dc24132931b990e1831e01b425254982a72f554ccaf7e127a93</citedby><cites>FETCH-LOGICAL-c433t-9e7b09c98d92a5dc24132931b990e1831e01b425254982a72f554ccaf7e127a93</cites><orcidid>0000-0001-6861-5261 ; 0000-0002-1607-6777 ; 0000-0003-2927-370X ; 0000-0003-4597-0281 ; 0000-0001-7694-6730 ; 0000-0002-3266-0842 ; 0000-0003-3372-442X ; 0000-0002-1320-4163 ; 0000-0001-6454-8030</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6010740/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6010740/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27900,27901,53765,53767</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29930489$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002354468$$DAccess content in National Research Foundation of Korea (NRF)$$Hfree_for_read</backlink></links><search><creatorcontrib>Kim, Do Jun</creatorcontrib><creatorcontrib>Kim, Woo Jin</creatorcontrib><creatorcontrib>Lim, Myoungnam</creatorcontrib><creatorcontrib>Hong, Yoonki</creatorcontrib><creatorcontrib>Lee, Seung-Joon</creatorcontrib><creatorcontrib>Hong, Seok-Ho</creatorcontrib><creatorcontrib>Heo, Jeongwon</creatorcontrib><creatorcontrib>Lee, Hui-Young</creatorcontrib><creatorcontrib>Han, Seon-Sook</creatorcontrib><title>Plasma CRABP2 as a Novel Biomarker in Patients with Non-Small Cell Lung Cancer</title><title>Journal of Korean medical science</title><addtitle>J Korean Med Sci</addtitle><description>Lung cancer is the most common cause of cancer-related mortality worldwide. We previously reported the identification of a new genetic marker, cellular retinoic acid binding protein 2 (CRABP2), in lung cancer tissues. The aim of this study was to assess plasma levels of CRABP2 from patients with non-small cell lung cancer (NSCLC).
Blood samples that were collected from 122 patients with NSCLC between September 2009 and September 2013 were selected for the analysis, along with samples from age- (± 5 years), sex-, and cigarette smoking history (± 10 pack-years [PY])-matched controls from the Korea Biobank Network. The control specimens were from patients who were without malignancies or pulmonary diseases. We measured plasma levels of CRABP2 using commercially available enzyme-linked immunosorbent assay kits.
The mean age of the NSCLC patients was 71.8 ± 8.9 years, and the median cigarette smoking history was 32 PY (range, 0-150 PY). Plasma CRABP2 levels were significantly higher in patients with NSCLC than in the matched controls (37.63 ± 28.71 ng/mL vs. 24.09 ± 21.09 ng/mL,
< 0.001). Higher plasma CRABP2 levels were also correlated with lower survival rates in NSCLC patients (
= 0.014).
Plasma CRABP2 levels might be a novel diagnostic and prognostic marker in NSCLC.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biomarkers, Tumor</subject><subject>Carcinoma, Non-Small-Cell Lung</subject><subject>Female</subject><subject>Humans</subject><subject>Lung Neoplasms</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Original</subject><subject>Prognosis</subject><subject>Receptors, Retinoic Acid - blood</subject><subject>Republic of Korea</subject><subject>Survival Rate</subject><subject>의학일반</subject><issn>1011-8934</issn><issn>1598-6357</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNpVUctOWzEUtFArXu0HsEFetoubnuNHbG8qhatCkSIaUbq2HMcXTO4D7Buq_j0OoajdnIc8M8ejIeQEYcK5mH65X3d5wgB1WScBld4jhyiNrqZcqndlBsRKGy4OyFHO9wBMSsb3yQEzhoPQ5pBcLVqXO0fr69nZglGXqaNXw1No6VkcOpfWIdHY04UbY-jHTH_H8a4A-upn59qW1qGU-aa_pbXrfUgfyPvGtTl8fO3H5Nf5t5v6ezX_cXFZz-aVF5yPlQlqCcYbvTLMyZVnAjkzHJfGQEDNMQAuBZNMCqOZU6yRUnjvGhWQKWf4Mfm80-1TY9c-2sHFl3472HWys-ubSysYR61UwX7dYR82yy6sfPGRXGsfUiz-_rww_3_p413RebJTQFACisCnV4E0PG5CHm0Xsy_OXR-GTbYMpJYwBcACxR3UpyHnFJq3Mwh2m5ndZma3mZXVbjMrnNN___fG-BsSfwbjL5EV</recordid><startdate>20180625</startdate><enddate>20180625</enddate><creator>Kim, Do Jun</creator><creator>Kim, Woo Jin</creator><creator>Lim, Myoungnam</creator><creator>Hong, Yoonki</creator><creator>Lee, Seung-Joon</creator><creator>Hong, Seok-Ho</creator><creator>Heo, Jeongwon</creator><creator>Lee, Hui-Young</creator><creator>Han, Seon-Sook</creator><general>The Korean Academy of Medical Sciences</general><general>대한의학회</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>ACYCR</scope><orcidid>https://orcid.org/0000-0001-6861-5261</orcidid><orcidid>https://orcid.org/0000-0002-1607-6777</orcidid><orcidid>https://orcid.org/0000-0003-2927-370X</orcidid><orcidid>https://orcid.org/0000-0003-4597-0281</orcidid><orcidid>https://orcid.org/0000-0001-7694-6730</orcidid><orcidid>https://orcid.org/0000-0002-3266-0842</orcidid><orcidid>https://orcid.org/0000-0003-3372-442X</orcidid><orcidid>https://orcid.org/0000-0002-1320-4163</orcidid><orcidid>https://orcid.org/0000-0001-6454-8030</orcidid></search><sort><creationdate>20180625</creationdate><title>Plasma CRABP2 as a Novel Biomarker in Patients with Non-Small Cell Lung Cancer</title><author>Kim, Do Jun ; Kim, Woo Jin ; Lim, Myoungnam ; Hong, Yoonki ; Lee, Seung-Joon ; Hong, Seok-Ho ; Heo, Jeongwon ; Lee, Hui-Young ; Han, Seon-Sook</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c433t-9e7b09c98d92a5dc24132931b990e1831e01b425254982a72f554ccaf7e127a93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biomarkers, Tumor</topic><topic>Carcinoma, Non-Small-Cell Lung</topic><topic>Female</topic><topic>Humans</topic><topic>Lung Neoplasms</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Original</topic><topic>Prognosis</topic><topic>Receptors, Retinoic Acid - blood</topic><topic>Republic of Korea</topic><topic>Survival Rate</topic><topic>의학일반</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kim, Do Jun</creatorcontrib><creatorcontrib>Kim, Woo Jin</creatorcontrib><creatorcontrib>Lim, Myoungnam</creatorcontrib><creatorcontrib>Hong, Yoonki</creatorcontrib><creatorcontrib>Lee, Seung-Joon</creatorcontrib><creatorcontrib>Hong, Seok-Ho</creatorcontrib><creatorcontrib>Heo, Jeongwon</creatorcontrib><creatorcontrib>Lee, Hui-Young</creatorcontrib><creatorcontrib>Han, Seon-Sook</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Korean Citation Index</collection><jtitle>Journal of Korean medical science</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kim, Do Jun</au><au>Kim, Woo Jin</au><au>Lim, Myoungnam</au><au>Hong, Yoonki</au><au>Lee, Seung-Joon</au><au>Hong, Seok-Ho</au><au>Heo, Jeongwon</au><au>Lee, Hui-Young</au><au>Han, Seon-Sook</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Plasma CRABP2 as a Novel Biomarker in Patients with Non-Small Cell Lung Cancer</atitle><jtitle>Journal of Korean medical science</jtitle><addtitle>J Korean Med Sci</addtitle><date>2018-06-25</date><risdate>2018</risdate><volume>33</volume><issue>26</issue><spage>e178</spage><epage>e178</epage><pages>e178-e178</pages><issn>1011-8934</issn><eissn>1598-6357</eissn><abstract>Lung cancer is the most common cause of cancer-related mortality worldwide. We previously reported the identification of a new genetic marker, cellular retinoic acid binding protein 2 (CRABP2), in lung cancer tissues. The aim of this study was to assess plasma levels of CRABP2 from patients with non-small cell lung cancer (NSCLC).
Blood samples that were collected from 122 patients with NSCLC between September 2009 and September 2013 were selected for the analysis, along with samples from age- (± 5 years), sex-, and cigarette smoking history (± 10 pack-years [PY])-matched controls from the Korea Biobank Network. The control specimens were from patients who were without malignancies or pulmonary diseases. We measured plasma levels of CRABP2 using commercially available enzyme-linked immunosorbent assay kits.
The mean age of the NSCLC patients was 71.8 ± 8.9 years, and the median cigarette smoking history was 32 PY (range, 0-150 PY). Plasma CRABP2 levels were significantly higher in patients with NSCLC than in the matched controls (37.63 ± 28.71 ng/mL vs. 24.09 ± 21.09 ng/mL,
< 0.001). Higher plasma CRABP2 levels were also correlated with lower survival rates in NSCLC patients (
= 0.014).
Plasma CRABP2 levels might be a novel diagnostic and prognostic marker in NSCLC.</abstract><cop>Korea (South)</cop><pub>The Korean Academy of Medical Sciences</pub><pmid>29930489</pmid><doi>10.3346/jkms.2018.33.e178</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0001-6861-5261</orcidid><orcidid>https://orcid.org/0000-0002-1607-6777</orcidid><orcidid>https://orcid.org/0000-0003-2927-370X</orcidid><orcidid>https://orcid.org/0000-0003-4597-0281</orcidid><orcidid>https://orcid.org/0000-0001-7694-6730</orcidid><orcidid>https://orcid.org/0000-0002-3266-0842</orcidid><orcidid>https://orcid.org/0000-0003-3372-442X</orcidid><orcidid>https://orcid.org/0000-0002-1320-4163</orcidid><orcidid>https://orcid.org/0000-0001-6454-8030</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1011-8934 |
| ispartof | Journal of Korean Medical Science, 2018, 33(26), , pp.1-9 |
| issn | 1011-8934 1598-6357 |
| language | eng |
| recordid | cdi_nrf_kci_oai_kci_go_kr_ARTI_4231877 |
| source | PubMed Central |
| subjects | Aged Aged, 80 and over Biomarkers, Tumor Carcinoma, Non-Small-Cell Lung Female Humans Lung Neoplasms Male Middle Aged Original Prognosis Receptors, Retinoic Acid - blood Republic of Korea Survival Rate 의학일반 |
| title | Plasma CRABP2 as a Novel Biomarker in Patients with Non-Small Cell Lung Cancer |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-24T13%3A35%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_nrf_k&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Plasma%20CRABP2%20as%20a%20Novel%20Biomarker%20in%20Patients%20with%20Non-Small%20Cell%20Lung%20Cancer&rft.jtitle=Journal%20of%20Korean%20medical%20science&rft.au=Kim,%20Do%20Jun&rft.date=2018-06-25&rft.volume=33&rft.issue=26&rft.spage=e178&rft.epage=e178&rft.pages=e178-e178&rft.issn=1011-8934&rft.eissn=1598-6357&rft_id=info:doi/10.3346/jkms.2018.33.e178&rft_dat=%3Cproquest_nrf_k%3E2058506001%3C/proquest_nrf_k%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c433t-9e7b09c98d92a5dc24132931b990e1831e01b425254982a72f554ccaf7e127a93%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2058506001&rft_id=info:pmid/29930489&rfr_iscdi=true |